×
About 5,043 results

ALLMedicine™ Myasthenia Gravis Center

Research & Reviews  1,780 results

ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records...
https://doi.org/10.1080/21678421.2021.1946084
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Longinetti E, Sveinsson O et. al.

Dec 3rd, 2021 - Objective:To determine if inflammation in proximity of the motor unit may contribute to neurodegeneration in amyotrophic lateral sclerosis (ALS). Methods: We identified all patients diagnosed in Sweden with concurrent ALS and multiple sclerosis (M...

Open thoracoabdominal aortic aneurysm repair in a patient with myasthenia gravis.
https://doi.org/10.1093/icvts/ivab331
Interactive Cardiovascular and Thoracic Surgery; Uehara K, Fujiwara Y et. al.

Dec 2nd, 2021 - Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder and rarely coexists with aortic aneurysms requiring open repair. A 66-year-old patient with MG underwent extended thoraco-abdominal aortic aneurysm (TAAA) repair 16 years afte...

Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627335
Journal of Immunology Research; Duan W, Peng Y et. al.

Dec 1st, 2021 - Tacrolimus is a second-line immunosuppressant in myasthenia gravis (MG) therapy, which is mainly used in combination with corticosteroids to reduce steroid dose and maintain the effect of immunotherapy. However, few studies have focused on the eff...

Post-Operative Outcomes Associated with Open versus Robotic Thymectomy: A Propensity Ma...
https://doi.org/10.1053/j.semtcvs.2021.11.011
Seminars in Thoracic and Cardiovascular Surgery; Soder SA, Pollock C et. al.

Nov 29th, 2021 - To compare post-operative outcomes associated with thymectomy performed using either open or robotic approaches. Retrospective cohort study from a single-center prospective registry consisting of patients undergoing thymectomy between 2000 and 202...

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT03971422

Nov 29th, 2021 - The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).

see more →

Guidelines  4 results

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 5th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

The Association of British Neurologists' myasthenia gravis guidelines.
https://doi.org/10.1111/nyas.13503
Annals of the New York Academy of Sciences; Sussman J, Farrugia ME et. al.

Nov 10th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critical...
https://doi.org/10.1097/CCM.0000000000002027
Critical Care Medicine; Murray MJ, DeBlock H et. al.

Oct 19th, 2016 - To update the 2002 version of "Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient." A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of n...

International consensus guidance for management of myasthenia gravis: Executive summary.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114
Neurology Sanders DB, Wolfe GI et. al.

Jul 1st, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

see more →

Drugs  50 results see all →

Clinicaltrials.gov  46 results

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT03971422

Nov 29th, 2021 - The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT04982289

Nov 18th, 2021 - Participants have the option to enroll in an Open-label Extension (OLE) Period to receive ALXN1830 up to 58 weeks (including follow-up period).

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT04115293

Nov 9th, 2021 - The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to rece...

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05067348

Nov 8th, 2021 - This study is a randomized, double-blind, placebo-controlled study, to be conducted at 6 study sites. Approximately 64 subjects will be enrolled. Patients with MG who are positive for anti-AChR antibodies will be enrolled. Patients who do not have...

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
https://clinicaltrials.gov/ct2/show/NCT03759366

Oct 29th, 2021 - The study will consist of an up to 4-week Screening Period, 26-week Primary Evaluation Treatment Period, an additional (up to) to 208-week Extension Period, and an 8-week Safety Follow-up Period.

see more →

News  132 results

Myasthenic Crisis After Recurrent COVID-19 Infection
https://www.mdedge.com/fedprac/article/244023/coronavirus-updates/myasthenic-crisis-after-recurrent-covid-19-infection
CPT Adam M. Spanier, MD, USA, CPT James I. Gragg, DO, USA

Aug 9th, 2021 - COVID-19 is still in the early stages of understanding, although it is known to be complicated by individual patient comorbidities. The management and treatment of COVID-19 continues to quickly evolve as more is discovered regarding the virus.

AAN Issues Formal Position Statement on COVID-19 Vaccine
https://www.medpagetoday.com/neurology/generalneurology/93862

Aug 2nd, 2021 - Based on existing evidence, neurologists should recommend COVID-19 vaccination to their patients, a newly released American Academy of Neurology (AAN) paper said. "Barring the rare circumstance of an absolute contraindication to available vaccine ...

Fast Five Quiz: Refresh and Test Your Knowledge of Myasthenia Gravis
https://www.medscape.com/viewarticle/899540

Jul 6th, 2021 - Myasthenia gravis (MG) is a relatively rare autoimmune disorder in which antibodies form against nicotinic acetylcholine (ACh) postsynaptic receptors at the neuromuscular junction of the skeletal muscles. It is a type II hypersensitivity immune re...

Potential First-in-Class, Targeted Therapy for Myasthenia Gravis
https://www.medscape.com/viewarticle/953330

Jun 17th, 2021 - Efgartigimod (argenx) is an effective and well-tolerated therapy for patients with generalized myasthenia gravis (gMG), new research suggests. Results from the phase 3, randomized, placebo-controlled ADAPT trial showed that reduction in disease bu...

New Botulism Guidelines Focus on Mass-Casualty Events
https://www.medscape.com/viewarticle/952251

Jun 1st, 2021 - Botulinum toxin is said to be the most lethal substance known. Inhaling just 1-3 nanograms of toxin per kilogram of body mass constitutes a lethal dose.  Now the Centers for Disease Control and Prevention (CDC) has published the first comprehensiv...

see more →

Patient Education  5 results see all →